Sunshine Biopharma (SBFM) Launches Everolimus In Canada
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion
April 21, 2025 8:31 AM EDTFORT LAUDERDALE, FL / ACCESS Newswire / April 21, 2025 / Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Everolimus in the Canadian generic prescription drugs market.
Everolimus is a generic equivalent of the brand name Afinitor®. Everolimus is indicated for the treatment of (i) advanced renal cell carcinoma, (ii) breast cancer in post-menopausal women with advanced HER2-negative genotype, (iii) progressive... More
